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ABSTRACT
Objectives The value of healthcare data is being 
increasingly recognised, including the need to improve 
health dataset utility. There is no established mechanism 
for evaluating healthcare dataset utility making it difficult 
to evaluate the effectiveness of activities improving the 
data. To describe the method for generating and involving 
the user community in developing a proposed framework 
for evaluation and communication of healthcare dataset 
utility for given research areas.
Methods An initial version of a matrix to review datasets 
across a range of dimensions was developed based on 
previous published findings regarding healthcare data. This 
was used to initiate a design process through interviews 
and surveys with data users representing a broad range 
of user types and use cases, to help develop a focused 
framework for characterising datasets.
Results Following 21 interviews, 31 survey responses 
and testing on 43 datasets, five major categories and 
13 subcategories were identified as useful for a dataset, 
including Data Model, Completeness and Linkage. 
Each sub- category was graded to facilitate rapid and 
reproducible evaluation of dataset utility for specific use- 
cases. Testing of applicability to >40 existing datasets 
demonstrated potential usefulness for subsequent 
evaluation in real- world practice.
Discussion The research has developed an evidenced- 
based initial approach for a framework to understand the 
utility of a healthcare dataset. It is likely to require further 
refinement following wider application and additional 
categories may be required.
Conclusion The process has resulted in a user- centred 
designed framework for objectively evaluating the likely 
utility of specific healthcare datasets, and therefore, should 
be of value both for potential users of health data, and for 
data custodians to identify the areas to provide the optimal 
value for data curation investment.
INTRODUCTION
Health Data Research UK (HDR UK) was 
established to unite the UK’s health data to 
enable discoveries that improve people’s 
lives.1 By making health data available 
to researchers and innovators, it will be 
possible to more rapidly develop improved 
understanding of disease and approaches 
to prevent, treat and cure them. During the 
establishment of HDR UK an initial ‘listening 
exercise’ was carried out, collating responses 
across the landscape of health data users, 
which reported that the major perceived 
barriers to use of data for research and inno-
vation were issues regarding data access and 
data quality.2
It is generally accepted that secondary use 
of health data for research and development 
has huge potential value but a significant 
amount of work to improve the data will be 
required to make such routine data useful.3 
One difficulty is that precisely which improve-
ments that provide most value in this context 
remain unknown. For example, ‘quality’ of 
datasets for most users is usually composed of 
a view of technical ‘data quality’ dimensions 
such as completeness, in addition to subjec-
tive assessment of factors related to a specific 
use case.4
The recently published National Data 
Strategy highlights the importance of high- 
quality data for the UK, and specifically refer-
ences the lack of standardised approaches 
Summary
What is already known?
 ► The concept of data quality is well established, but 
the overall usefulness of a dataset for a purpose 
may be impacted by numerous additional factors.
 ► One of the stated challenges in using UK health data 
for research is perceived lack of useful datasets.
 ► There is no currently available standard framework 
for evaluating the utility of a healthcare dataset for a 
particular purpose.
What does this paper add?
 ► We describe the process by which a framework 
for understanding the usefulness of a dataset was 
developed.
 ► Information on the key characteristics related to 
dataset utility, based on surveys, interviews and 
testing, were used to provide a standard framework 
for dataset evaluation according to purpose.
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for assessing and managing data quality in this context.5 
With the potential for future widespread investment in 
the general area of ‘improving data’, it is important that 
this is evidence based and focused on the areas that will 
have the greatest impact. A widely adopted standard tool 
for assessing the broad usefulness of a dataset would help 
to inform this future development and investment.
Previous studies are available which address specific 
aspects of the broad area of ‘data quality’ in health, but 
none presents a similar framework as suggested here. 
For example, evaluation of data quality improvement 
programmes are described focusing on specific quality 
dimensions such as accuracy and precision.6 There are 
approaches described for evaluating quality of medical 
device data,7 use of rule based approaches for data quality 
evaluation and management,8 and outputs of workshops 
focusing on health data quality issues.9 There has been a 
suggestion that quality informatics may become a specific 
area of health informatics.10 Despite such recognition of 
the importance of data quality for widespread uses, eval-
uation of data utility for specific purposes has remained 
difficult.11
The aim of this study was to develop a proposed frame-
work for evaluating the usefulness of a health dataset, 
across a range of potential use cases, to rapidly iden-
tify those which are likely to be most applicable for the 
specific purpose, and to provide an objective method of 
evaluating or categorising a dataset in order to rationally 
deploy data curation resources. In addition to the needs 
across the health data community, HDR UK in particular 
requires a means of determining improvement across 
seven publicly funded HDR Hubs: consortia of organi-
sations involved in improving data and providing access 
to it for research and innovation.12 The Hubs present 
multiple, parallel experiments for improving data, and so 
understanding their effectiveness in improving datasets 
for particular use cases allows for effective evaluation and 
could focus future investment. This presented an oppor-
tunity and need to develop a data utility framework as a 
service development project for HDR UK.
METHODS
The initial framework was developed based on the broad 
areas relating to data utility, which had been identified 
from previously published evidence.13 We adopted a 
user centred co- design approach which was designed to 
result in an understanding of the areas of user interest in 
data usefulness.14 Given the absence of consensus on an 
existing approach, it was important to gain a broad under-
standing of the topic, so a combination of interviews, 
surveys and user testing was used to help achieve diversity 
of inputs into the development of the framework, in line 
with standard practice in user centred design.15 16
We, therefore, focused on the major issues relating to 
health dataset utility by interviewing a range of data users 
in the domain, followed by collation of additional views 
from key stakeholders across the community through a 
survey consultation process. This was done to create and 
discover the main areas of interest for such a framework 
across a range of user groups and use cases. These findings 
were then used to further refine and develop a proposed 
Data Utility Framework that could be subsequently used 
and iterated by the community.
The framework aimed to indicate the ‘utility’ of a 
dataset for researchers for a particular purpose based 
on a set of key attributes, which would be classified using 
predefined criteria into subsequent arbitrary qualitative 
categories (bronze, silver, gold and platinum). Principles 
for the framework included that the bronze- platinum 
categories should differentiate utility for any given dimen-
sion in a progressive manner that each dimension should 
have objective criteria that will allow users to determine 
a utility score (initially through self- evaluation) that a 
greater score can only be achieved if the dataset meets the 
criteria of the previous categories as well as an additional 
criterion for the new score and that there is no expecta-
tion that all datasets should achieve a particular classifi-
cation since some use cases may only require a minimum 
standard, while others may require greater utility scores 
for their purposes.
For interviews, the interviewee’s particular data require-
ments were used as a basis for discussion, and users artic-
ulated the ways by which they determine the utility of 
a dataset for their particular use case, that is, how they 
determined if a dataset was ‘useful’ for their purpose. 
They were specifically asked their views regarding various 
components of an initial proposed framework which was 
based on the previous HDR UK scoping information 
(online supplemental table 1). The number of times 
interviewees refer to specific components of the draft 
framework were quantified, to capture interest in the 
items as presented. This methodology is a common user- 
centred design approach, to identify features that a range 
of individuals would like to see represented.17
Interviewees were selected based on a segmented 
sample to ensure representation from multiple sectors, 
including artificial intelligence (AI)/tech firms, large 
pharmaceutical companies, National Health Service/
data custodians and academics (figure 1). Forty individ-
uals were contacted to request an interview. Of these, 8 
did not respond, 10 declined to be interviewed, 3 were 
unable to schedule a time and 21 were finally inter-
viewed. Interviews were held in April and May 2020 using 
an online meeting platform, and these were recorded to 
support transcription of the discussion.
Interviews were semistructured (online supplemental 
table 2). Questions were sent at least 24 hours before the 
interview, in addition to the initial framework. Consent of 
the participants was taken from their initial agreement to 
participate in the interview process—all were informed 
of the nature of the project in developing the tool.18 As 
the approach to develop the framework was service devel-
opment work and did not include patients or staff in 
their clinical roles, ethical approval was not required—as 
confirmed by the Health Research Authority.19
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The interviewees were asked to comment on the impor-
tance of dimensions within the proposed framework, 
and to suggest any dimensions which were not originally 
included, but were not otherwise directed and were free 
to discuss whichever aspects they felt most important.
Qualitative content analysis was used on the outputs of 
interviews to establish the relative interest in the various 
dimensions. This included an estimation of the catego-
ries for the proposed ‘medallion’ ratings (online supple-
mental table 3).
In June 2020, a survey was issued to the interviewee 
list, as well as HDR UK’s Data Officer Community, with a 
request for all recipients to share with their own contacts. 
The survey (online supplemental table 4) requested input 
on the revised matrix. Responses from 30 individuals were 
received with some respondents spread across multiple 
sectors (figure 2). The content analysis was repeated to 
identify refinements and develop the second version of 
the matrix (online supplemental table 5).
Following the survey, the second version of the frame-
work was included in a wider consultation, which was 
publicly open online from August to September 2020. In 
addition, the second version of the framework was applied 
to 43 existing datasets across seven HDR Hubs, with feed-
back provided from each team on the potential suit-
ability and applicability of the framework. These datasets 
include routinely collected clinical data, genomic data, 
national datasets and imaging datasets. The feedback 
from this process was used to develop the final version of 
the framework but given that no existing ‘gold standard’ 
framework existed, formal testing of performance was 
not carried out as part of this process.
RESULTS
Participant characteristics
The interviewees represented a range of different sectors 
(figure 1). All were required to use health data for 
research, or support others in doing so, as part of their 
professional context.
Original framework comments
All interviews (21) emphasised the importance of a 
comprehensive dataset metadata, describing the nature 
Figure 1 Bar chart showing breakdown of interviewees by sector.
Figure 2 Bar chart showing breakdown of survey respondents by sector.
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and scope of the data collection. This information enabled 
users to identify the utility and relevance of a dataset for 
specific use cases. A number of interviews (nine) empha-
sised the importance of a readily available data dictionary 
and ability to interrogate the dataset at a data element 
level. Beyond typical dataset descriptions, users empha-
sised the requirement to understand data provenance, 
especially in the case of data consolidated from multiple 
sources, where the provenance may differ across data 
elements. The number of mentions of each dimension of 
the original framework is provided in table 1 (note that 
these are a reflection of interest, rather than support, as 
they may be comments in support of the dimension or 
disagreement):
Description: characteristics and service
Interviewees drew little distinction between dimensions 
in the description and characteristics and service catego-
ries, as many of the elements relate to the information 
that is available about the dataset, known as the metadata. 
Several users, particularly from industry, noted the impor-
tance of upfront clarity regarding the uses applicable for 
the dataset, something that is not currently widely avail-
able. A number of interviewees described the available 
of additional resources and information on the dataset 
including previous academic publications, documen-
tation of frequently asked questions and a contact for 
whom they could reach with questions as a key factor of 
data utility.
Beyond descriptive metadata, ‘access’ was a key 
consideration for data users sourcing data from outside 
their organisations. Users with commercial use cases 
(including companies developing and supplying data and 
machine learning products, and pharmaceutical compa-
nies) wanted indicators of which datasets were available 
for commercial use, in order to minimise enquiries into 
unsuitable data sources. Researchers noted that the 
amount of time required to gain approval for data access 
was a deciding factor in selecting datasets (and sometimes 
research questions) and commercial data users also high-
lighted this as a risk. The means of data access; (eg, direct 
download, use of a secure environment, via an internal 
analysis team) was noted as an important factor impacting 
time and costs for commercial organisations accessing 
data. This emphasis led to the creation of a separate cate-
gory focusing on service.
The service category was subject to significant attention 
at the testing stage. Respondents noted that clarity was 
required on the role of the research environment, as well 
as refining the wording on the categories for timeliness.
Scale
The initial elements within the Scale category were 
perceived to be useful by interviewees. Some interviewees 
(3) mentioned the pathway coverage dimension and 
those from pharmaceutical background indicated that 
the longitudinal patient journey helped explain health 
outcomes. Many survey respondents (14 of the 20) who 
indicated their feelings deemed this element as either 
important or very important.
While nine interviewees specifically commented on 
the ‘coverage’ field, interview questions relating to the 
number of expected items did not yield meaningful 
answers due to the significant variability across use 
cases. Therefore, the number of entries element was 
excluded from the final matrix. Additionally, pharmaceu-
tical companies wanted details of coverage on a specific 
number of patients meeting multiple requirements. 
Duration was excluded since as feedback suggested that 
‘length of patient follow- up’ was an element of particular 
interest. Depth was also excluded since users valued the 
details of what was measured rather than the number of 
things being measured. Missing data and missing data 
handling was a topic of interest but was excluded from 
the final framework since it was difficult to agree the 
optimal method, but suggestions that this be included in 
the additional documentation and support section of the 
metadata.
‘Technical’ quality dimensions
Throughout the surveys and interviews, the aspects of 
‘technical’ data quality, defined here as those listed by 
the Data Management Association (DAMA), were seen 
as important, mentioned by 11 interviewees, but no indi-
cation could be given of specific required or expected 
levels for the dimensions. This led to the supplementa-
tion of the DAMA dimensions (Completeness, Unique-
ness, Timeliness, Validity, Accuracy and Consistency) 
with an additional element relating to the data manage-
ment process itself, which was supported by several (six) 
interviewees. This additional data management process 
element was considered by all but one survey respondent 
to be either important (14) or very important (7).
Added value
The additional information available about a dataset was 
generally considered to be of importance by interviewees 
and respondents. The majority of discussions in this 
area related to the ability to link the dataset with others, 
with this being mentioned 10 times by interviewees. 
Many survey respondents (12) felt that this element 
was very important. Respondents also commented that 
data enrichment was important (13) but there was no 
direct discussion on this dimension from the interviews. 
Current usage was relatively useful but was not mentioned 
directly by interviewees or in the respondent’s comments. 
Data access requests were said to be a useful indicator of 
the level of utility of the dataset and more likely to be 
understandable with a functional and operational data 
governance process. There were mixed feelings among 
the respondents for this dimension deeming it low impor-
tance. For the provenance of access request dimension 
where there were only two specific comments in each 
of the interview and survey responses. The added value 
section was reduced in scope for the final matrix given 
this response.
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Table 1 Table showing number of interview respondents commenting on each item from the original framework, to gain an 
understanding of an end users view of the initial framework categories





Description Metadata completeness Level of metadata completed 2
Metadata quality Richness of metadata completion—including 
within required formats and quality of qualitative 
fields
5
Characteristics and Service Data source The modality or source of data (eg, Electronic 
Health Record, study specific)
14
Data model The data model or schema used by the dataset 
(eg, Observational Medical Outcomes Partnership 
(OMOP), Informatics for Integrating Biology and 
the Bedside (i2b2))
16
Data dictionary Provided documented data dictionary and 
terminologies
9
Provenance The original source or jurisdiction of the dataset
Usage restrictions The df to use the data for different purposes (eg, 
commercial licences, consent, expiry)
6
Format The technical presentation of the data format (eg, 
Digital Imaging and Communications in Medicine 
(DICOM) images vs Portable Graphics Format 
(PNG))
3
Timeliness How quickly the data can be provided—in a 
useful timescale
7
Fairness of the data Extent to which the data are findable, accessible, 
interoperable and reusable
0
  Phenome Extent and description of included patients/
conditions (links with Phenome work re 
standards)
2
Scale Coverage No of individuals, data points, lab tests, images, 
etc included in the dataset
9
Duration Length of time to which the data relates 3
Depth Amount of information available per individual (eg, 
number of fields/records, types of data)
3
Quality Completeness The proportion of data entries that should be 
populated are populated (and inverse—proportion 
that should not be populated are not)
11
Missing data handling Description of missing value handling and default 
values
4
Consistency/uniformity Data are presented in the required format and a 
similar wayfor example, field types, date formats
1
Uniqueness Lack of duplication 3
Validity Data are valid based on acceptable ‘rules’ for 
example, age between 0 and 120, pregnancy 
in male patients, physiological readings within 
normal ranges
7
Accuracy/verification The extent to which the data reflects the ‘real- 
world’, for example, level of certainty that fields 
are accurate
6
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The final proposed version of the data utility framework 
following the user design feedback is provided in figure 3.
DISCUSSION
The findings of this study have provided an evidence- 
based initial approach for a proposed framework for 
identifying and understanding the main factors that are 
related to the utility of a healthcare dataset for secondary 
purposes across a range of industries and use cases. This 
has allowed development of a data quality matrix and clas-
sification system, which will be further refined through 
testing and implementation. The real- world usefulness of 
such a framework will be evaluated following implemen-
tation and feedback from users as well as usage statistics 
of particular datasets in relation to their framework score 
and classification. It is believed to be the first successful 
attempt to create a semi- structured framework for char-
acterising health datasets on usability and allowing users, 
regardless of their specific use- case, to identify in advance 
whether a dataset would be useful for their purposes.
The main strengths of the study are that this is a prac-
tical and robust approach to a problem that has been 
theoretically reviewed but not addressed in an objective 
manner previously. The range of different stakeholders, 
through multiple cycles, and the repeated improvement 
and testing have allowed for the development of a frame-
work that is able to be adapted to different data types and 
able to be implemented in real- life situations.
However, by necessity, this approach has had to use a 
non- random group of respondents, due to the process 
and potential selection bias of the survey respondents. 
The sampling strategy was developed based on a system-
atic but pragmatic approach to collect a range of views 
to be gathered from different organisations and sectors 
to ensure all main stakeholder groups were represented. 
Any potential bias could lead to a matrix that was incom-
plete, or had unnecessary emphasis on particular catego-
ries, and only large- scale feedback will determine these 
aspects. The continuous development of the matrix 
during the process was appropriate given the pragmatic 
nature of the project in the absence of an existing stan-
dard practice, but a more structured approach would 
have identified in advance the stages and cycles of devel-
opment. This methodological limitation impacts the 
ability of the matrix in its present form to be used for 
other data contexts without further development and 
here we make no claims regarding cross- sector applica-
bility. Given these limitations, future iterations of the 
framework are likely to evolve from the original version 
presented here based on real world usage and feedback. 
However, further research is required to identify the 
‘effectiveness’ of the framework in terms of identifying 
areas to address through data improvement activities and 
then demonstrating that usability of the dataset increased 
subsequently. It is not known at this stage the power of 
the framework or its potential use in other circumstances.
The framework is likely to require further development 
as it is tested on an increasingly wide range of health 
datasets. This development will take several forms: the 
refinement of the existing categories, the addition of 
new categories, integration into tools and the creation of 
extensions. The refinement of the existing categories will 
continue as more feedback is received through the testing 
process. One key development is likely to be ‘normalisa-
tion’ of the categories—currently the breakdown is based 
on the surveys and interviews, as well as initial testing on 
>40 datasets. As the tool is applied to many more datasets, 
it may be necessary to adjust the categories to ensure an 
appropriate distribution across the existing categories in 
the UK health landscape.
Similarly, it is possible that further categories may be 
added. For example, during the development, a cate-
gory on ‘Research Environment’ was proposed. However, 
an inability to reconcile the varying tensions between 
the current status of research environments across UK 
data custodians, user requests from particular sectors 
and the principles for Trusted Research Environments, 
this category was not included in the final version of the 
framework.
The integration of the framework into tools will allow 
for its value to be realised in practice. In isolation, it 
provides a view of a given dataset, however, the power of 
such a framework approach comes with the ability for an 
individual to specify their requirements in a catalogue, 
such as the HDR Innovation Gateway, and use their 
requirements from the framework to remove the datasets 
which would not be fit for their purposes. The framework 
was deliberately designed to be able to be applied in a 





Added value Linkage/mapping Ability to link with other datasets 10
Transformations/
derivations
Level of derived data and descriptions, manual 
versus Natural Language Processing, etc
1
Accuracy/verification Level of manual verification/sampling 0
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general manner, however, it was solely tested on datasets 
and users relating to biomedical data and applications. 
Further work is required to explore whether it can be 
usefully applied to other data types, and if specific exten-
sions are required for certain data modalities, such as 
imaging data.
CONCLUSION
In conclusion, we have proposed a codesigned and 
evidence- based health dataset utility framework, for poten-
tial widespread evaluation and use, which will be integrated 
into HDR UK’s ambitions to make health data more useful 
for research and enable discoveries that improve people’s 





Proportion of metadata (as in 
the current metadata 
specification) which is available 
in the expected format  
This element will be calculated automatically based on the level of metadata available on the Gateway, 







documentation in addition to 
the data dictionary 
Past journal articles 
demonstrate that 




extracting and use of 
data, Dataset FAQS 
available, Visual data 
model provided 
As Silver, plus dataset 
publication was 
supported with a 
journal article 
explaining the 
dataset in detail, or 
dataset training 
materials 
As Gold, plus support 
personnel available to 
answer questions 
Data Model Availability of clear, documented data model 
Known and accepted 
data model but some 
key field un-coded or 
free text 
Key fields codified 
using a local standard 
Key fields codified 
using a national or 
international 
standard 
Data Model conforms to a 
national standard and key 
fields codified using a 
national / international 
standard 
Data Dictionary Provided documented data 




into local data 
dictionary which is 
available online 
Dictionary relates to 
national definitions 
Dictionary is based on 
international standards 
and includes mapping 
Provenance Clear description of source and 
history of the dataset, providing 
a "transparent data pipeline" 
Source of the dataset is 
documented 
Source of the dataset 
and any 
transformations, 
rules and exclusions 
documented 
All original data items 
listed, all 
transformations, 
rules and exclusion 
listed and impact of 
these 
Ability to view earlier 
versions, including 
versions before any 
transformations have 
been applied data (in line 
with deidentification and 
information governance 
approval) and review the 







The level of maturity of the data 
quality management processes 





available for the dataset 
Evidence that the 
data management 
plan has been 
implemented is 
available 
  Externally verified 
compliance with the data 
management plan, e.g. by 
International Organization 
for Standardization (ISO), 
Care Quality Commission 
(CQC), Information 
Commissioner’s Office 





Technical data quality 
dimensions: Completeness, 
Uniqueness, Accuracy, Validity, 
Timeliness and Consistency 
 These elements will be calculated with data profiling tools, and the category breakdown evaluated 




Pathway coverage Representation of multi-
disciplinary healthcare data 
Contains data from a 
single speciality or area 
Contains data from 
multiple specialties 
or services within a 
single tier of care 
Contains multimodal 
data or data that is 
linked across two 
tiers (e.g. primary 
and secondary care) 
Contains data across more 
than two tiers 
Length of follow up Average timeframe in which a 
patient appears in a dataset 
(follow up period) 
Between 1 - 6 months Between 6 - 12 
months 
Between 1 - 10 years More than 10 years 
Access & 
Provision 
Allowable uses Allowable dataset usages as per 
the licencing agreement, 
following ethical and 
information governance 
approval 
Available for specific 




profit (e.g. charity, 
public sector) uses 
only 
Available for limited 
commercial uses (e.g. 
relating to a specific 
domain), in addition 
to academic and 
other non-
commercial uses 
Available for wider  
commercial uses (in line 
with ethical and 
information governance 
approval), and addition to 
academic and other non-
commercial uses 
Time Lag Lag between the data being 
collected and added to the 
dataset 




Effectively real-time data 
Timeliness Average data access request 
timeframe 
Less than 6 months Less than 3 months Less than 1 month Less than 2 weeks 
Value & Interest 
Linkages Ability to link with other 
datasets 
Identifiers to 
demonstrate ability to 
link to other datasets 
Available linkages 





List of restrictions on 
the type of linkages 




navigable links to 
linked datasets via a 
Digital Object 
Identifier (DOI) or 
Uniform Resource 
Locator (URL) 
Existing linkage with 
reusable or downstream 
approvals 
Data Enrichments Data sources enriched with 
annotations, image labels, 
phenomes, derivations, Natural 
Language Processing (NLP) 
derived data labels 
The data include 
additional derived 
fields, or enriched data. 
The data include 
additional derived 
fields, or enriched 
data used by other 
available data 
sources. 
The derived fields or 
enriched data were 
generated from, or 
used by, a peer 
reviewed algorithm. 
The data includes derived 
fields or enriched data 
from a national report.  
 
Figure 3 Final version of the proposed data utility framework based on data user feedback.
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lives. The tool will be tested on datasets currently discover-
able through the Innovation Gateway, and feedback from 
this process will be used to refine the framework as appli-
cable to the range of potential use cases. Such as frame-
work may also provide objective evidence to demonstrate 
the benefit of specific data improvement and ‘curation’ 
activities, including the potential for providing a return- 
on- investment type understanding of work in data.
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